OBJECTIVE: To determine the effect of long-term desmopressin therapy in enuretic patients on the levels of antidiuretic hormone (ADH) during and after the end of therapy. PATIENTS AND METHODS: The study comprised 25 outpatients (18 boys and seven girls) aged 8-12 years at the start of therapy and 12-16 years at the end. The morning (08.00 hours) plasma ADH level was determined before treatment (T0) with desmopressin and 2 years after (T1) ending the therapy. Seven of the 25 patients evaluated had monosymptomatic (simple enuresis, SE) and 18 had other symptoms (complex enuresis, CE). RESULTS: In the patients with SE, the mean (SD) duration of therapy was 305 (183) days and they were reevaluated 2.5 (0.67) years later. Of 18 patients with ...
INTRODUCTION: Nocturnal enuresis is a common pediatric condition with limited treatment options. In ...
Title: Predicting antidiuretic response to desmopressin in nocturnal enuresis Authors: Sevasti Ka...
OBJECTIVE: To determine the pharmacodynamic properties of a new oral lyophilisate formulation of des...
OBJECTIVE: To determine the effect of long-term desmopressin therapy in enuretic patients on the le...
Background/aim: The data concerning the effects of desmopressin on water/electrolyte disturbances of...
Background: Enuresis is defined as a normal void occurring at an inappropriate social time or place....
Purpose: Desmopressin is an evidence-based medicine level 1, category A therapy for monosymptomatic ...
Primary nocturnal enuresis (PNE) is a distressing condition, particularly in severe cases (>= 3 wet ...
Objective: Nocturnal enuresis is a common diagnosis in patients referred to pediatric and pediatric...
Introduction/Background : Many recent treatment guidelines have advocated the importance of a full n...
Purpose: Desmopressin is a well established and effective therapy for nocturnal enuresis. Water into...
BACKGROUND: The aim of this study was to evaluate the effectiveness of treatment with methylphenidat...
PURPOSE: Urological management of spina bifida patients is controversial. The goals of therapy of ...
Background: The first-line drug therapy for patients with nocturnal enuresis (NE) associated with no...
Introduction & Objective: Nocturnal enuresis as a common disorder in children can create many proble...
INTRODUCTION: Nocturnal enuresis is a common pediatric condition with limited treatment options. In ...
Title: Predicting antidiuretic response to desmopressin in nocturnal enuresis Authors: Sevasti Ka...
OBJECTIVE: To determine the pharmacodynamic properties of a new oral lyophilisate formulation of des...
OBJECTIVE: To determine the effect of long-term desmopressin therapy in enuretic patients on the le...
Background/aim: The data concerning the effects of desmopressin on water/electrolyte disturbances of...
Background: Enuresis is defined as a normal void occurring at an inappropriate social time or place....
Purpose: Desmopressin is an evidence-based medicine level 1, category A therapy for monosymptomatic ...
Primary nocturnal enuresis (PNE) is a distressing condition, particularly in severe cases (>= 3 wet ...
Objective: Nocturnal enuresis is a common diagnosis in patients referred to pediatric and pediatric...
Introduction/Background : Many recent treatment guidelines have advocated the importance of a full n...
Purpose: Desmopressin is a well established and effective therapy for nocturnal enuresis. Water into...
BACKGROUND: The aim of this study was to evaluate the effectiveness of treatment with methylphenidat...
PURPOSE: Urological management of spina bifida patients is controversial. The goals of therapy of ...
Background: The first-line drug therapy for patients with nocturnal enuresis (NE) associated with no...
Introduction & Objective: Nocturnal enuresis as a common disorder in children can create many proble...
INTRODUCTION: Nocturnal enuresis is a common pediatric condition with limited treatment options. In ...
Title: Predicting antidiuretic response to desmopressin in nocturnal enuresis Authors: Sevasti Ka...
OBJECTIVE: To determine the pharmacodynamic properties of a new oral lyophilisate formulation of des...